Study #2025-1099
A modular phase I/II, open-label, multi-centre study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of AZD3632 monotherapy or in combination with anticancer agents in participants with advanced haematologic malignancies with KMT2Ar, NPM1m, or other genotypes associated with HOX overexpression
MD Anderson Study Status
Enrolling
Treatment Agent
Description
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Study phase:
Physician name:
Ghayas Issa
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.?